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Background: Filamentous fungi are frequently recovered from respiratory cultures of individuals with CF.
Methods: A CF cohort database was utilized to determine filamentous fungal prevalence and risk factors.
Results: The prevalence of filamentous fungal isolation increased from 2.0% in 1997 to 28.7% in 2007. The odds of isolating filamentous fungi
during a quarter was greater in CF adults [pb0.001], during chronic oral antibiotic use [p=0.002] and increased with each 10% drop in FEV1
percent predicted [p=0.005], while inhaled corticosteroids surprisingly decreased the likelihood [p=0.012]. The direction of these effects
persisted after excluding individuals with ABPA. A sub-analysis determined older age [p=0.019] and use of inhaled antibiotics [p=0.011] were
independent risk factors for onset of fungal colonization.
Conclusions: This study suggests that isolation of filamentous fungi in CF at JHH has increased and risk factors include older age, decreased lung
function, and chronic oral antibiotics.
© 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Filamentous fungi; Prevalence; Corticosteroids1. Introduction
Cystic fibrosis (CF) is an autosomal recessive disorder
caused by mutations in the cystic fibrosis transmembrane
regulator (CFTR) gene and occurs in about 1 in 2500 live births
in populations of European descent [1]. Most of the morbidity
and mortality in CF populations is attributed to respiratory
infections and the lung microbiology of these individuals is
closely monitored by routine culture [2].
Individuals with CF are affected by a unique set of opportunistic
bacteria that are often recovered from lung cultures in a specific
succession [3–5]. Filamentous fungi are also routinely isolated
from individuals with CF, but how these organisms integrate into
this sequence, and the effects of fungi on lung function are not⁎ Corresponding author. 615 N Wolfe Street, 6th Floor, Baltimore, MD 21205,
United States.
E-mail address: crsudfeld@gmail.com (C.R. Sudfeld).
1569-1993/$ - see front matter © 2009 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2009.11.010completely understood [6]. A recent study by Amin et al. deter-
mined that colonization with Aspergillus fumigatus was associated
with hospital admissions in CF patients [7]. However, the effect of
fungal colonization on lung function remains unclear, especially in
the absence of Allergic bronchopulmonary aspergillosis (ABPA).
The Johns Hopkins Cystic Fibrosis Integrative Microbiology
Database (CFIMD) was created to investigate risk factors and
outcomes associated with less common CF organisms. The pri-
mary purposes of this study were to evaluate epidemiologic
patterns for fungal isolation in CF over the last decade and
determine clinical risk factors for recovery of filamentous fungi.
2. Methods
2.1. Population
All pediatric and adult CF patients seen in the Johns Hopkins
Hospital (JHH) CF clinics from January 1, 1997 to Decemberd by Elsevier B.V. All rights reserved.
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Foundation patient registry (CFFPR) were included in the study
cohort (n=614). There were no exclusion criteria.
2.2. Design and procedures
The CFIMD is a retrospective cohort study designed to
investigate the lung microbiology of the CF population at Johns
Hopkins by linking medical record and microbiology data. The
microbiology component of the CFMID contains expectorated
sputum, bronchoaveolar lavage, and throat swab culture data for
CF patients meeting the inclusion criteria. The following data
are linked for every clinic visit which included an airway
culture: age, sex, height (cm), weight (kg), body mass index
(BMI kg/m2), percent predicted forced expiratory volume at 1 s
(FEV1%), and current medications. FEV1% was calculated
using the Hankinson et al. and Wang et al. equations [8,9].
Allergic bronchopulmonary aspergillosis (ABPA) status was
determined by clinicians caring for the patient based on clinical
symptoms, elevated total serum immunoglobulin (IgE) levels,
and elevated serum Aspergillus-specific IgE levels. The
CFIMD was analyzed by quarter; therefore height, weight,
BMI, and FEV1% were averaged for the quarter if an individual
had data from more than one clinic visit during the quarter. The
age variable was analyzed as the age at the midpoint of the
quarter for all individuals.
For primary analysis we compared clinical encounters from
quarters with isolation of at least one filamentous fungus to
those without fungus isolation. In addition, secondary analyses
included the prevalence of filamentous fungal, bacterial, and
yeast species isolated 1997–2007 along with changes in
recovery rates over the study period.
2.3. Laboratory methods
The fungi recovered were identified to genus or species by
protocols developed at The Johns Hopkins Hospital based on
phenotypic and genotypic characteristics. Identification may be
as short as 24–48 h or may require 3–4 weeks based on growth
rates and availability of reagents or kits. Over the course of the
study period the macroscopic and microscopic protocols were
constant. Molecular assays such as DNA probe (Gen-Probe,
Inc. San Diego, CA) confirmation of dimorphic fungi and
sequencing techniques were added to the algorithm progres-
sively in later years; however these techniques are usually not
required to identify the common fungi such as Aspergillus spp.
typically recovered from CF patients.
In brief the laboratory used macroscopic evaluation to
determine fungal growth characteristics including relative growth
rates, growth/no growth on different media and at various
temperatures, colony texture, pigmentation (melanized, non-
melanized, and specific colors), and assessment of macroscopic
structures visualized by eye or 10× hand lens. The microscopic
evaluation included examining hyphal characteristics such as
diameter and presence/absence of septa, clamp connections, non-
multiplying chlamydospores, or spores (asexual or sexual).
Additional phenotypic biochemical assays were utilized whenneeded. Examples include: urease, carbohydrate metabolic and
cell wall enzymes, specific protoeases, and chitin assays. Peptide
Nucleic Acid-Fluorescence in situ Hybridization (PNA FISH)
(AdvanDx Inc. Woburn, MA) reagents and occasionally
serologic assays were used for yeast differentiation.
2.4. Statistical analysis
When analyzing for differences in clinical characteristics
between quarters with fungal isolation compared to quarters
with no fungal isolation, continuous variables were assessed
using the Student′s t-test and categorical variables using the χ2
test. Logistic regression was utilized to determine independent
effects of clinical characteristics on the odds of isolating
filamentous fungi during a quarter. Possible confounders were
determined by literature review and biologic plausibility. The
variables included in the model for filamentous fungi were age,
BMI, FEV1%, and pulmonary therapies including antifungals,
inhaled antibiotics, inhaled corticosteroids, oral corticosteroids,
chronic oral antibiotics (prescribed on two or more clinic visits
but not to treat an exacerbation and excluding azithromycin),
number of cultures per quarter, and year of clinic visit. Inhaled
antibiotics were also subcategorized as inhaled tobramycin,
other inhaled aminoglycosides (not including tobramycin),
inhaled colistin, and other inhaled medications. As ABPA could
confound the results, we also performed subgroup analyses
adjusted for confounders and limited the data to individuals
never diagnosed with ABPA during the study period.
We also performed a sub-analysis of risk factors for onset of
fungal colonization. Onset of colonization was defined as the
first quarter in a series of two or more quarters, occurring no
more than 1 quarter apart, with isolation of the same fungal
species. Quarters with transient fungal isolation and those
subsequent to the initial quarter of colonization onset were
excluded from this analysis in order to determine risk factors for
confirmed colonization onset. We also performed this analysis
limiting the data to individuals never diagnosed with ABPA
during the study period.
During exploratory analysis, the shape of the relationship
between each variable and odds of isolating filamentous fungi
were determined to be linear except for the number of cultures
per quarter, age, and year of clinic visit. In order to model the
nonlinear relationships, the number of cultures per quarter, age,
and year of clinic visit were analyzed categorically. A p-
valueb0.05 was considered statistically significant for all
analyses. Non-collinearity of variables and other assumptions
of logistic regression were confirmed [10]. Sensitivity analysis
for missing data was performed using the last observation
carried forward method. Analyses were conducted using
STATA 10.0 Special Edition (STATACORP, College Station,
TX). The Institutional Review Board at the Johns Hopkins
University School of Medicine approved the study.
3. Results
A total of 614 individuals with CF underwent airway
cultures at the JHH adult and pediatric clinics from 1997 to
Table 1
Prevalence of bacterial, filamentous fungal and yeast species recovered
1997–2007.
# of individuals (%)
n=614
# of isolates (%)
n=14,288
Filamentous fungi and yeast
Aspergillus fumigatus 223 (36.3) 885 (6.0)
Aspergillus (non-
fumigatus)
160 (26.1) 107 (0.7)
Trichosporon spp. 13 (2.1) 44 (0.3)
Scedosporium spp. 14 (2.3) 21 (0.1)
Other filamentous
fungi a
31 (5.0) 41 (0.5)
Yeast b 175 (28.5) 324 (2.2)
Bacteria
Pseudomonas spp. 513 (83.6) 5209 (35.7)
Staphylococcus
aureus
493 (80.3) 4640 (31.8)
Haemophilus
influenzae
217 (35.3) 382 (2.6)
Burkholderia cepacia
complex
32 (5.2) 98 (0.7)
Other bacteria 486 (79.1) 2537 (17.4)
a Alternaria, Curvularia, Fusarium, Paecilomyces, Penicillium, and Exo-
phiala species.
b Candida albicans, Candida glabrata, and undifferentiated yeast species.
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individuals were seen at 9170 clinic visits during the 11 year
study period, and their average follow-up time was 5.98 years.
14,288 organisms were recovered from the study population
(1.6 organisms per airway culture), of which 13,166 (90.3%)
were classified bacteria, 1098 (7.5%) filamentous fungi, and
324 (2.2%) yeast. The isolates were further differentiated into
148 distinct bacterial or fungal species as classified by the JHH
diagnostic laboratory.
3.1. Prevalence of fungal and yeast species
The total number of CF patients in the database steadily
increased from 247 in 1997 to 397 during 2007. The percentage
of patients recovering bacterial or yeast species each year
remained relatively constant: between 94–98% for bacteria and
1–3% for yeast, with only minor fluctuations. In contrast, the
percentage of CF patients growing filamentous fungi signifi-
cantly increased over time (Fig. 1). In 1997 only 2.0% of JHH
CF patients grew filamentous fungi; by 2007 the incidence had
increased to 28.7%.
Overall, at least one filamentous fungi was recovered from
respiratory culture from 254 (41.3%) members of the study
population from 1997 to 2007. Only 4 fungal isolated (0.004%)
were recovered from individuals previously receiving a lung
transplant. A. fumigatus was isolated from 223 (36.3%)
individuals and was the most prevalent filamentous fungal
species (Table 1). Non- A. fumigatus species, including A.
flavus, A. niger, and A. terreus, were recovered from 160
(26.1%) individuals, while Scedosporium spp. and Trichos-
poron spp. (more yeast-like however in this case acts like a
filamentous fungi) were isolated in 2.3% (n=14) and 2.1%
(n=13) respectively. Other filamentous fungal species were
recovered from 31 (5.0%) individuals and included Alternaria,
Curvularia, Fusarium, Paecilomyces, Penicillium, and Exo-
phiala species. Yeast species were found in 28.5% (n=175) of
the study population during 1997–2007. Candida albicans was
the most frequently isolated yeast, but exact proportions were
not able to be calculated because yeast isolates other thanFig 1. Percentage of individuals recovering at least one filamentous fungal
species from lung culture during each year 1997–2007.Cryptococcus neoformans were not differentiated by species
during the early part of the study period.
3.2. Clinical characteristics of CF individuals with cultures
positive for filamentous fungi
When comparing individual characteristics in quarters where
at least one filamentous fungal species was recovered to
quarters with no filamentous fungi isolation, significant
differences were found in mean age (23.8 vs. 17.8; pb0.001),
FEV1% (63.3 vs.72.2 pb0.001), BMI (20.3 vs. 19.6;
pb0.001), and number of cultures (2.7 vs. 1.6; pb0.001)
(Table 2). In addition, there were differences in pulmonary
therapies during the quarters with fungal isolation: oral
corticosteroids (2.5% vs. 1.0%; pb0.001), chronic oral
antibiotics (10.8% vs. 3.7%; pb0.001), and inhaled antibiotics
(25.9% vs. 10.6%; pb0.001). Recovery of filamentous fungi
did not vary by season: 51.0% of quarters with isolation of
filamentous fungi occurred during July–December (p=0.530).
3.3. Risk factors for isolation of filamentous fungi
Logistic regression was used to determine the independent
effects of age, FEV1%, BMI and pulmonary therapies on the
odds of isolating filamentous fungi after adjusting for
confounders (Table 3). Most strikingly, for every 10% decrease
in FEV1%, the odds of isolating filamentous fungi during a
quarter independently increased by 5.0% (95% CI 2.0%–9.0%;
p=0.005). Age was also significantly associated with filamen-
tous fungi: adults (≥18 years old) were 51% more likely to
Table 2
Characteristics of quarters with isolation of filamentous fungi compared to
quarters recovering only bacteria or yeast species.
Filamentous fungi
recovered (n=1012)
No filamentous fungi
recovered (n=7575)
p-
value
Age 23.8 17.8 b0.001
FEV1 percent
predicted
63.3 72.2 b0.001
BMI (kg/m2) 20.3 19.6 b0.001
# Cultures
during quarter
2.7 1.6 b0.001
% During quarter
3 and 4 a
51.0 51.7 0.660
Pulmonary therapies (%)
Antifungals 2.6 1.4 0.005
Inhaled
corticosteroid
3.7 2.7 0.077
Oral
corticosteroid
2.5 1.0 b0.001
Inhaled
antibiotics
25.9 10.6 b0.001
Chronic oral
antibiotics
10.8 3.7 b0.001
a Assessment of seasonality.
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adjustment for confounders, use of chronic oral antibiotics (OR
1.66, 95% CI 1.20–2.31; p=0.002) was the only pulmonary
therapy that significantly increased the odds of fungal isolation.
There was only a statistically non-significant trend toward
inhaled antibiotics increasing the likelihood of fungal isolation
(OR 1.35, 95% CI 0.99–1.85; p=0.054). Subgroup analysis
also found no significant increases in fungal isolation when
differentiating inhaled antibiotics by type: inhaled tobramycin
(OR 1.15, 95% CI 0.85–1.55; p=0.378), non-tobramycin
inhaled aminoglycosides (OR 0.76, 95% CI 0.29–1.96;
p=0.564), or inhaled colistin (OR 1.42, 95% CI 0.94–2.15;
p=0.100).Table 3
Logistic regression: determining independent effects of variables on isolation of fila
Quarters with fungal isolation
[n=1012]
Variable Unadjusted
OR
95% CI p-
value
Age c under 18 (Ref.) 1.00 – –
18+ 2.53 2.20 to 2.90 b0.001
FEV1 percent predicted
c (per 10% decrease) 1.12 1.10 to 1.14 b0.001
BMI (per 1 point increase) 1.05 1.03 to 1.06 b0.001
Pulmonary therapies
Antifungals c 1.84 1.19 to 2.84 0.006
Inhaled corticosteroid c 1.38 0.96 to 1.97 0.078
Oral corticosteroid 2.50 1.58 to 3.94 b0.001
Chronic oral antibiotic c 3.25 2.57 to 4.11 b0.001
Inhaled antibiotic c 2.94 2.51 to 3.44 b0.001
a Analysis excludes fungal positive quarters subsequent to first quarter of coloniz
b Adjusted for all listed variables and number of visits per quarter and year.
c Significant post adjustment (pb.05).Antifungal antibiotics (OR 0.47, 95% CI 0.25–0.88;
p=0.019) and inhaled corticosteroids (OR 0.55, 95% CI
0.35–0.88; p=0.012) were found to be protective against
recovery of filamentous fungi. After adjustment for confoun-
ders, neither low BMI (OR 0.99, 95% CI 0.96–1.01; p=0.365)
nor oral corticosteroids (OR 1.23, 95% CI 0.63–2.42; p=0.542)
was found to increase the risk of fungal isolation. Year of
isolation, which can be seen as an indicator of laboratory
sensitivity, fluctuations in fungal exposure, or change in patient
management, showed an increase in the odds of isolating fungi
between 2000 and 2001 with much more gradual increases
during 1997–2000 and 2001–2007.
We also performed a sub-analysis of risk factors for fungal
colonization onset, which was defined as the first quarter in a
series of two or more quarters, occurring no more than 1 quarter
apart, with isolation of the same fungal species (Table 3). There
were 126 colonization onset quarters in 99 individuals; 79
(79.8%) individuals were colonized once, 16 (16.2%) indivi-
duals colonized twice, and 5 (5.1%) individuals three times.
There were 108 (85.7%) A. fumigatus colonizations, 7 (5.6%)
Trichosporon spp. colonizations, 3 (2.4%) Aspergillus flavus
colonizations, and 1 (0.8%) Scedosporium spp. colonization.
The only significant risk factors for fungal colonization onset
were adulthood (N18 years) (OR 3.60; 95% CI 1.23–10.51;
p=0.019) and inhaled antibiotic use (OR 3.84; 95% CI 1.37–
10.79; p=0.011). These relationships persisted when limiting
the data to A. fumigatus colonizations and when analyzing only
the data for onset of first colonization.
Additional subgroup analyses were performed to account for
the potential effect of individuals with ABPA on the results
(Table 4). When individuals ever diagnosed with ABPA during
the study period were removed from the analysis, there was still
an increased risk of fungal isolation with lower lung function
(p=0.009), older age (pb0.001), and use of chronic oral
antibiotics (pb0.001). Use of inhaled corticosteroids was again
associated with decreased likelihood of fungal isolation
(pb0.005). This analysis was also performed looking at
quarters with fungal colonization as the outcome of interestmentous fungi and stratifying by colonization and transient isolation.
Quarters with fungal isolation
[n=1012]
First quarter of fungal
colonization a [n=126]
Adjusted ORb 95% CI p-
value
Adjusted
ORb
95% CI p-
value
1.00 – – 1.00 – –
1.51 1.20 to 1.88 b0.001 3.60 1.23 to 10.51 0.019
1.05 1.02 to 1.09 0.005 0.84 0.70 to 1.01 0.067
0.99 0.96 to 1.01 0.365 0.91 0.80 to 1.05 0.196
0.47 0.25 to 0.88 0.019 0.92 0.16 to 5.16 0.925
0.55 0.37 to 0.88 0.012 0.13 0.02 to 1.06 0.056
1.23 0.63 to 2.42 0.542 – – –
1.66 1.20 to 2.31 0.002 1.34 0.54 to 3.35 0.526
1.35 0.99 to 1.85 0.054 3.84 1.37 to 10.79 0.011
ation and quarters with transiently isolated fungi.
Table 4
Logistic regression: determining independent effects of variables on isolation of filamentous fungi and subset of colonized quarters excluding individuals ever
diagnosed with ABPA during 1997–2007.
Quarters with fungal isolation [n=881] First quarter of fungal colonization a [n=111]
Variable Adjusted ORb 95% CI p-value Adjusted ORb 95% CI p-value
Age c under 18 (Ref.) 1.00 – – 1.00 – –
18+ 1.56 1.23 to 2.01 b0.001 2.49 0.80 to 7.71 0.115
FEV1 percent predicted
c (per 10% decrease) 1.05 1.01 to 1.10 0.009 1.07 0.92 to 1.25 0.094
BMI (per 1 point increase) 0.99 0.96 to 1.03 0.729 0.93 0.80 to 1.09 0.380
Pulmonary therapies
Antifungals 0.29 0.03 to 2.83 0.285 – – –
Inhaled corticosteroid c 0.47 0.28 to 0.79 0.005 0.14 0.18 to 1.14 0.067
Oral corticosteroid 1.90 0.64 to 5.69 0.249 – – –
Chronic oral antibiotic c 1.92 1.33 to 2.77 b0.001 1.25 0.46 to 3.37 0.658
Inhaled antibiotic d 1.42 1.01 to 1.98 0.043 5.46 1.71 to 17.41 b0.001
a Analysis excludes fungal positive quarters subsequent to first quarter of colonization and quarters with transiently isolated fungi.
b Adjusted for all listed variables and number of visits per quarter and year.
c Significant post adjustment (pb.05) for fungal isolation.
d Significant post adjustment (pb.05) for both fungal isolation and first quarter of colonization.
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(pb0.001), chronic use of oral antibiotics (p=0.002), and
inhaled corticosteroids (p=0.009) decreased the odds of fungal
colonization. In this sub-analysis oral corticosteroid use
increased the odds of fungal colonization. We also performed
the analysis of risk factors for onset of colonization in the
absence of individuals ever diagnosed with ABPA (Table 4).
The only risk factor that was significantly associated with
colonization onset was use of inhaled antibiotics (pb0.001).
Overall, less than 5% of the data were missing and sensitivity
analyses for missing data were robust to our conclusions.4. Discussion
This retrospective cohort study was conducted to determine
epidemiologic trends of fungal infection in individuals with CF and
identify independent risk factors for recovery of filamentous fungi.
This single center data suggest that there has been a significant
increase in the prevalence of filamentous fungi in CF respiratory
cultures over the last decade, with increases in bothAspergillus and
non-Aspergillus fungal species. Similar increases have been noted
in CF studies in the United States and the United Kingdom,
although the cause is not completely understood [11,12]. Neither
the fungal culture media nor the isolation algorithm at Johns
Hopkins changed over the course of our study period; thus
variability in lab procedures is not likely to be the basis for the
increase. The average age of the JHH CF cohort substantially older
in 2007 (20.11 years) compared to 1997 (14.8 years) and this may
partially account for the increase, since we determined older age
was a risk factor for fungal isolation. This increase in fungal
isolation is in contrast to yeast isolation with organisms such as C.
albicans, for which prevalence remained relatively constant during
the study period. The overall trend suggests that the observed
increase in filamentous fungi may not be due solely to greater
frequency and length of antibiotic use, as this might be expected to
increase yeast prevalence as well. It also suggests that individualswith CF may have a particular susceptibility to infection with
filamentous fungi.
The rates of recovery of filamentous fungi in this study
cohort are similar to those reported in other CF cohorts: 41.3%
of the study population had at least one filamentous fungal
species during the study period, with A. fumigatus recovery
from 36.3% of individuals [11–14]. The bacterial prevalence by
species was also similar to those reported in other CF cohorts,
suggesting that the findings may be generalizable to the broad
CF population [2,15–17].
Analysis of the data in connection with patient characteristics
and clinical practice data was revealing. Even after adjustment for
confounders, one of the strongest risk factors for filamentous
fungus isolation is decreased lung function. Each 10% drop in
FEV1% below 100% predicted increases the odds of recovering
filamentous fungi during a quarter by 5.0% (95%CI 2.0%–9.0%).
In addition, the data provide insight into the relationship
between fungal isolation and certain pulmonary therapies. After
adjustment for confounders including severity of lung disease, the
treatment practice that most significantly increased the odds of
recovering filamentous fungi was use of chronic oral antibiotics.
Chronic oral antibiotics were defined as use during two or more
clinic visits (excluding azithromycin and antibiotics prescribed to
treat an exacerbation). The most commonly used oral antibiotics in
this setting were trimethoprim/sulfamethoxazole and minocycline.
Perhaps more surprising was the finding that use of inhaled
corticosteroids was associated with fewer positive filamentous
fungal cultures (not yeast such as Candida species). This appears
counterintuitive as inhaled corticosteroids have been associated
with development of invasive Aspergillus infections in non-CF
populations and A. fumigatus sensitization in CF [18–21]. In
addition, Ren et al. reported an increase in Aspergillus recovery
with inhaled corticosteroids from a cohort study of the
Epidemiologic Study of Cystic Fibrosis; however these results
were not adjusted for confounding as lung microbiology was a
secondary outcome of the study [22]. In our analysis before
adjustment for confounding, inhaled corticosteroids seemed to
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inhaled corticosteroids were protective. One possible explanation
for the protective findings is that individuals with ABPA are often
simultaneously treated with inhaled corticosteroids and oral
antifungal antibiotics, thus decreasing the likelihood of fungal
isolation in culture. However, even after excluding data from
patients with ABPA from the analysis, we still found inhaled
corticosteroids decreased the likelihood of fungal isolation.
Another potential mechanism for the observed finding may be
that inhaled corticosteroids increase susceptibility to certain
bacterial species which may be able to out-compete filamentous
fungi for growth in the lungs. Ren et al. also found that use of
inhaled corticosteroids significantly increased the frequency of
Stenotrophomonas maltophilia and Burkholderia cepacia cul-
tures [22]. There has also been concern of an increased risk of
Pseudomonas aeruginosa acquisition with inhaled corticoster-
oids, howevermultiple studies have not found an association [22–
24]. Further longitudinal study of the effects of inhaled
corticosteroids on lung microbiology is warranted.
A sub-analysis examining risk factors for fungal colonization
onset found that older age and use of inhaled antibiotics were
significantly associated. Furthermore, when limiting the data to
individuals never diagnosedwithABPAuse of inhaled antibiotics
remained significantly associated. The direction of the effect of
other variables, like inhaled corticosteroids, was similar to the all
fungal analysis, however we likely did not have a large enough
sample size to find significant independent effects.
A major strength of this study is that it utilizes data on a large
CF cohort followed for over a decade. Many other studies of
fungal infection in CF patients have been limited by small
sample size, short follow-up, or lack of correlating clinical
details. Using data from a single center also offers the advantage
of laboratory uniformity, as the isolation algorithm was
consistent over the study period.
There are also some potential limitations to this study.
Detection bias may have occurred in sicker individuals who had
more respiratory tract cultures per quarter compared to healthier
individuals. Increased respiratory sampling in this group would
lead to an overestimation of the association between decreased
lung function and filamentous fungi. To specifically address
this potential bias however, we adjusted for the number of clinic
visits in our multivariate analyses. A second potential limitation
is that the recovery rate of yeast was significantly lower in this
study compared to results in studies which employed selective
yeast media [6]. The routine Johns Hopkins airway culture
algorithm likely underestimates the true prevalence of yeast
species. We were also unable to verify clinician diagnosis of
ABPA as defined by the Stevens et al. criteria since we were not
able to obtain antibody or skin test data [25]. As a result, there
may be minimal misclassification of ABPA diagnosis.
While this study found that lower lung function has a strong
association with recovery of filamentous fungi, we are not able
to determine if fungal isolation contributes to lower lung
function or is only a marker of more severe lung disease and
aggressive therapy. Large longitudinal studies investigating the
change in lung function over time would be needed to address
the effect of fungal infection on lung function. Furthermore,analyses would need to address the relationship by species as
each may vary in clinical impact. In particular, further attention
is warranted for species Trichosporon and Scedosporium, for
which pathogenicity has been suggested [26,27].
Our study demonstrates that there has been a steady increase
in the prevalence of filamentous fungi in respiratory cultures in
individuals with CF over the last decade. It also suggests that
older age, decreased lung function, and chronic oral antibiotics
are risk factors for isolating filamentous fungi. As the majority
of individuals with CF will at some point demonstrate
filamentous fungi in their respiratory tract, greater understand-
ing of the epidemiologic trends, risk factors and clinical
implications of fungal infection in CF is needed.
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